Evidence map›Paper›PMID 11181465›Full record

Trial reportCirculation2001

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.

M Crisby, G Nordin-Fredriksson, P K Shah, J Yano, J Zhu, J Nilsson

2 registry-linked trialsAbstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 218 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
218citing papers in PubMed, 3 pooled it
29.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02114697 phase4terminatedstarted 2014, after this paper: background citation

Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging

Ran2014Enrolled9Registered outcomes1Posted comparisons0ConditionsAtherosclerosisArmsLifestyle Modification, Statin therapy
PMID 18997196PMID 15135672PMID 10865837PMID 10961958PMID 11432882PMID 11687667PMID 11773180PMID 11877368PMID 12368635PMID 12476646PMID 12490960PMID 12655579other papers from this trial
Open the trial in the graph
NCT02679261 phase3completednot on this mapstarted 2016, after this paper: background citation

Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR)

TypeinterventionalSponsorHospital Universitari Vall d'Hebron Research InstituteRan2016 to 2021Enrolled220ConditionsBicuspid Aortic ValveArmsAtorvastatin, Placebo
3 · Its place in the literature

Who cites it

218 citing papers in PubMed, 3 syntheses or guidelines pooled it, 993 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.The Cochrane database of systematic reviews · 2013 · on this map
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2011
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Review

158 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

M CrisbyDepartment of Neurology, Huddinge University Hospital, Stockholm, Sweden.
G Nordin-Fredriksson
P K Shah
J Yano
J Zhu
J Nilsson
Malmö University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical benefits of lipid lowering with statins are attributed to changes in plaque composition leading to lesion stability, but supporting clinical data from human studies are lacking. Therefore, we investigated the effect of 3 months of pravastatin treatment on composition of human carotid plaques removed during carotid endarterectomy. METHODS AND

resultsConsecutive patients with symptomatic carotid artery stenosis received 40 mg/d pravastatin (n=11) or no lipid-lowering therapy (n=13; control subjects) for 3 months before scheduled carotid endarterectomy. Carotid plaque composition was assessed with special stains and immunocytochemistry with quantitative image analysis. Plaques from the pravastatin group had less lipid by oil red O staining (8.2+/-8.4% versus 23.9+/-21.1% of the plaque area, P<0.05), less oxidized LDL immunoreactivity (13.3+/-3.6% versus 22.0+/-6.5%, P<0.001), fewer macrophages (15.0+/-10.2% versus 25.3+/-12.5%, P<0.05), fewer T cells (11.2+/-9.3% versus 24.3+/-13.4%, P<0.05), less matrix metalloproteinase 2 (MMP-2) immunoreactivity (3.6+/-3.9% versus 8.4+/-5.3%, P<0.05), greater tissue inhibitor of metalloproteinase 1 (TIMP-1) immunoreactivity (9.0+/-6.2% versus 3.1+/-3.9%, P<0.05), and a higher collagen content by Sirius red staining (12.4+/-3.1% versus 7.5+/-3.5%, P<0.005). Cell death by TUNEL staining was reduced in the pravastatin group (17.7+/-7.8% versus 32.0+/-12.6%, P<0.05).

conclusions-Pravastatin decreased lipids, lipid oxidation, inflammation, MMP-2, and cell death and increased TIMP-1 and collagen content in human carotid plaques, confirming its plaque-stabilizing effect in humans.

Indexed as

Lipid MetabolismAgedApolipoprotein B-100Apolipoproteins BCarotid ArteriesCarotid Artery DiseasesCell Adhesion MoleculesCell DeathCholesterolCollagenDisease ProgressionEndarterectomy, CarotidFemaleHumansInflammationIn Situ Nick-End LabelingApolipoprotein B-100Apolipoproteins BCell Adhesion MoleculesCholesterolCollagenLipoproteinsMatrix Metalloproteinase 2MetalloendopeptidasesNF-kappa BPravastatinTissue Inhibitor of Metalloproteinases

Identifiers

PMID11181465
OpenAlexW1978644984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.